Safety and Immunogenicity of the Quadrivalent Human Papillomavirus Vaccine in HIV‐1–Infected Men | Zendy

Timothy Wilkin | Zendy; Jeannette Y. Lee | Zendy; Shelly Lensing | Zendy; Elizabeth A. Stier | Zendy; Stephen E. Goldstone | Zendy; J. Michael Berry | Zendy; Naomi Jay | Zendy; David M. Aboulafia | Zendy; David L. Cohn | Zendy; Mark H. Einstein | Zendy; Alfred J. Saah | Zendy; Ronald T. Mitsuyasu | Zendy; Joel M. Palefsky | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Safety and Immunogenicity of the Quadrivalent Human Papillomavirus Vaccine in HIV‐1–Infected Men

Author(s) -

Timothy Wilkin,

Jeannette Y. Lee,

Shelly Lensing,

Elizabeth A. Stier,

Stephen E. Goldstone,

J. Michael Berry,

Naomi Jay,

David M. Aboulafia,

David L. Cohn,

Mark H. Einstein,

Alfred J. Saah,

Ronald T. Mitsuyasu,

Joel M. Palefsky

Publication year - 2010

Publication title -

the journal of infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.69

H-Index - 252

eISSN - 1537-6613

pISSN - 0022-1899

DOI - 10.1086/656320

Subject(s) - medicine , seroconversion , anal cancer , adverse effect , vaccination , immunogenicity , men who have sex with men , cervical cancer , immunology , vaccine trial , clinical trial , multicenter aids cohort study , virology , cancer , viral disease , virus , antibody , human immunodeficiency virus (hiv) , sida , syphilis

Human immunodeficiency virus type 1 (HIV-1)-infected men are at increased risk for anal cancer. Human papillomavirus (HPV) vaccination may prevent anal cancer caused by vaccine types.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research